Compare CTSO & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | COCP |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 21.6M |
| IPO Year | 2008 | 2011 |
| Metric | CTSO | COCP |
|---|---|---|
| Price | $6.01 | $0.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.25 | $8.00 |
| AVG Volume (30 Days) | ★ 52.9K | 38.7K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,503,908.00 | $12,712,091.00 |
| Revenue This Year | $4.91 | N/A |
| Revenue Next Year | $13.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.30 | $0.76 |
| 52 Week High | $7.44 | $2.03 |
| Indicator | CTSO | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 73.08 | 25.00 |
| Support Level | $2.88 | $0.86 |
| Resistance Level | $7.44 | $1.11 |
| Average True Range (ATR) | 0.61 | 0.05 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 82.52 | 0.74 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.